Chun Yu Pan
Direktor/Vorstandsmitglied bei UWELL Biopharma, Inc.
Profil
Chun Yu Pan currently works at UWELL Biopharma, Inc., as Director.
Mr. Pan also formerly worked at Shangya Technology Co., Ltd., as Director-Supervisory Board and Vectorite Biomedical, Inc., as Director from 2011 to 2014.
Mr. Pan received his Masters Business Admin degree from Chinese Culture University.
Aktive Positionen von Chun Yu Pan
| Unternehmen | Position | Beginn |
|---|---|---|
UWELL Biopharma, Inc.
 UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Chun Yu Pan
| Unternehmen | Position | Ende |
|---|---|---|
| VECTORITE BIOMEDICAL INC. | Direktor/Vorstandsmitglied | - |
| SHANGYA TECHNOLOGY CO., LTD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Chun Yu Pan
| Chinese Culture University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SHANGYA TECHNOLOGY CO., LTD. | Health Technology |
| VECTORITE BIOMEDICAL INC. | Transportation |
| Private Unternehmen | 1 |
|---|---|
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Health Technology |